Get Premium to unlock powerful stock data
FRA:0NF0 (Canada)  
Mydecine Innovations Group Inc logo

Mydecine Innovations Group Inc

€ 0.62 (-2.36%) Jun 29
P/E:
At Loss
P/B:
0
Market Cap:
€ 3.26M ($ 3.40M)
Enterprise V:
€ 6.67M ($ 6.96M)
Volume:
4.77K
Avg Vol (2M):
1.16K
Also Trade In:
Volume:
4.77K
Market Cap €:
3.26M
Market Cap $:
3.40M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.16K
Enterprise Value €:
6.67M
Enterprise Value $:
6.96M
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Mydecine Innovations Group Inc
NAICS : 325411 SIC : 3741
789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2
Description
Mydecine Innovations Group Inc is a biopharma and life sciences company. It is committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use. Reinforcing Mydecine's commitment to mental health solutions is underpinned by the company's three main focuses: Clinical Trials focusing on Veterans, EMS, and First Responders with a PTSD indication; Research and Development building a robust portfolio of intellectual property around drug discovery and unique delivery mechanisms with relevant use patents and future patent applications and Modern technology utilizing for better clinical trial management and mental health wellbeing.
Name Current Vs Industry Vs History
Cash-To-Debt 0.06
Equity-to-Asset -0.71
Debt-to-Equity -1.31
Debt-to-EBITDA -0.54
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -43.96
Distress
Grey
Safe
Beneish M-Score 1.14
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 45.08
9-Day RSI 44.43
14-Day RSI 41.59
6-1 Month Momentum % -87.96
12-1 Month Momentum % -95.37

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.75
Quick Ratio 0.75
Cash Ratio 0.06
Days Sales Outstanding 1022

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -233.4

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -168820
Net Margin % -188260
ROE % -117.7
ROA % -69.13
ROIC % -118.31
ROC (Joel Greenblatt) % -636.94
ROCE % -88.8

Financials

FRA:0NF0's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 0.003
EPS (TTM) (€) -1.54
Beta 4.92
Volatility % 121.46
14-Day RSI 41.59
14-Day ATR (€) 0.076428
20-Day SMA (€) 0.64815
12-1 Month Momentum % -95.37
52-Week Range (€) 0.54 - 19.975
Shares Outstanding (Mil) 5.22

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Mydecine Innovations Group Inc Filings

Document Form Filing Date
No Filing Data